Vision Point Advisory Group, LLC Abb Vie Inc. Transaction History

Vision Point Advisory Group, LLC

$473 Million
Q3 2025

A detailed history of Vision Point Advisory Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Vision Point Advisory Group, LLC holds 3,586 shares of ABBV stock, worth $781,891. This represents 0.18% of its overall portfolio holdings.

Number of Shares

3,586

Previous 3,679 2.53%

Holding current value

$781,891

Previous $682,000 21.7%

% of portfolio

0.18%

Previous 0.16%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 07, 2025	SELL	$184.85 - $231.54 $17,191 - $21,533	-93 Reduced 2.53%	3,586 $830,000
Q2 2025 Jul 09, 2025	BUY	$170.16 - $206.27 $264,768 - $320,956	1,556 Added 73.29%	3,679 $682,000
Q1 2025 Apr 23, 2025	BUY	$169.2 - $216.66 $80,031 - $102,480	473 Added 28.67%	2,123 $444,000
Q4 2024 Feb 03, 2025	SELL	$164.99 - $203.87 $44,712 - $55,248	-271 Reduced 14.11%	1,650 $293,000
Q3 2024 Oct 15, 2024	SELL	$163.84 - $199.33 $89,456 - $108,834	-546 Reduced 22.13%	1,921 $379,000
Q2 2024 Aug 01, 2024	SELL	$154.79 - $180.76 $693,459 - $809,804	-4,480 Reduced 64.49%	2,467 $423,000
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $529,164 - $602,933	-3,311 Reduced 32.28%	6,947 $1.27 Million
Q4 2023 Feb 07, 2024	BUY	$137.6 - $154.97 $87,238 - $98,250	634 Added 6.59%	10,258 $1.59 Million
Q3 2023 Dec 06, 2023	BUY	$133.59 - $154.65 $26,851 - $31,084	201 Added 2.13%	9,624 $1.43 Million
Q2 2023 Aug 21, 2023	SELL	$132.51 - $164.9 $113,561 - $141,319	-857 Reduced 8.34%	9,423 $1.27 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $499,627 - $575,395	-3,455 Reduced 25.15%	10,280 $1.64 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $830,551 - $996,049	6,005 Added 77.68%	13,735 $2.22 Million
Q3 2022 Nov 17, 2022	BUY	$134.21 - $153.93 $26,707 - $30,632	199 Added 2.64%	7,730 $1.04 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $170,235 - $216,425	-1,237 Reduced 14.11%	7,531 $1.07 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $1.16 Million - $1.44 Million	8,768 New	8,768 $1.35 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $208,487 - $229,519	-2,038 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $437,221 - $590,295	-5,432 Reduced 72.72%	2,038 $218,000
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $277,403 - $325,580	-3,229 Reduced 30.18%	7,470 $654,000
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $553,503 - $740,669	7,544 Added 239.11%	10,699 $1.04 Million
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $29,025 - $44,005	-450 Reduced 12.48%	3,155 $240,000
Q4 2019 Jan 30, 2020	SELL	$72.13 - $90.25 $74,005 - $92,596	-1,026 Reduced 22.16%	3,605 $319,000
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $71,356 - $85,790	1,133 Added 32.39%	4,631 $346,000
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $2,628 - $3,359	40 Added 1.16%	3,498 $254,000
Q1 2019 May 10, 2019	BUY	$77.14 - $90.79 $266,750 - $313,951	3,458 New	3,458 $279,000

Others Institutions Holding ABBV

# of Institutions

4,382

Shares Held

1.3B

Call Options Held

16.1M

Put Options Held

10.9M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $386B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vision Point Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vision Point Advisory Group, LLC with notifications on news.

Account

Vision Point Advisory Group, LLC Abb Vie Inc. Transaction History